Scynexis stock surges on $214M BARDA contract for SCY-247
Scynexis Inc (SCYX) shares rose 10% premarket after securing a $214M contract from BARDA for SCY-247, a treatment for invasive candidiasis. The deal includes $18.5M for Phase 2 trials. SCY-247 has FDA designations and positive Phase 1 data. The company expects to fund its share of costs within its existing plan. SCYX does not anticipate changes to its guidance for SCY-770 or its cash runway into 2029.
How this was made
The 30-second read
Why it matters
The BARDA award provides up to $214 M, enabling Phase‑2 trials and strengthening the company's cash runway to 2029.
Market read
The contract is a material, first‑report event that moved the stock 10% pre‑market, offering a clear trading catalyst.
What to watch
Potential future funding gaps if trial results are not favorable; reliance on a single government contract.
Background
SCYX is a Jersey City‑based biotech developing SCY‑247 for invasive candidiasis, with orphan and fast‑track FDA designations.
Ticker impact
SCYX announced a BARDA contract worth up to $214 million, driving a 10% pre‑market share jump.
upward pressure as investors price in the new contract funding
Large BARDA award for a biotech with orphan designations; market already reacted with a 10% rise.
Market effects
Highlights continued government support for infectious‑disease biotech, may lift peer valuations.
Positive for U.S. biotech sector and Washington‑based pharma companies.
Shows BARDA's role in accelerating antimicrobial pipelines worldwide.
Counterpoint
If Phase‑2 data disappoint, the contract could be seen as a one‑off boost without long‑term upside.
Key entities
- companySCYX
Biotech firm developing SCY‑247.
- government_agencyBARDA
Biomedical Advanced Research and Development Authority.
